fasudil
Small moleculeexperimental
Fasudil (INN) is a potent Rho-kinase inhibitor and vasodilator. Since it was discovered, it has been used for the treatment of cerebral vasospasm, which is often due to subarachnoid hemorrhage, as well as to improve the cognitive decline seen in stroke patients. It has been found to be effective for the treatment of pulmonary hypertension. It has been demonstrated that fasudil could improve memory in normal mice, identifying the drug as a possible treatment for age-related or neurodegenerative memory loss. — Wikipedia
Clinical trial activity
19 trials · 20 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
14
Phase 3
5
Phase 4
1
Earliest trial started Jun 1, 2002 (NCT00120718)
Timeline
Indications
Approved for
Studied for
- Alzheimer Disease · Phase 2
- Amyotrophic Lateral Sclerosis · Phase 2
- Atherosclerosis · Phase 2
- Cardiovascular Diseases · Phase 2
- Carotid Stenosis · Phase 2
- Cognition Disorders · Phase 2
- Corticobasal Degeneration · Phase 2
- Dementia · Phase 2
- Hypercholesterolemia · Phase 2
- Macular Edema · Phase 3
- Ovarian Neoplasms · Phase 2
- Parkinsonian Disorders · Phase 2
- Prostatic Neoplasms · Phase 2
- Raynaud Disease · Phase 3
- Retinal Vein Occlusion · Phase 2/Phase 3
- Retinopathy of Prematurity · Phase 2/Phase 3
- Scleroderma, Systemic · Phase 3
- ST Elevation Myocardial Infarction · Phase 4
- Supranuclear Palsy, Progressive · Phase 2
Mechanism of action
- Rho-associated protein kinase 2INHIBITOR
ROCK2 inhibitor
- Rho-associated protein kinaseINHIBITOR
Rho-associated protein kinase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=S(=O)(c1cccc2cnccc12)N1CCCNCC1- Mol. weight
- 291.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL38380 ↗
- WikipediaFasudil ↗
- ChEMBLCHEMBL541388 ↗
Also known as
- 1-(5-isoquinolinesulfonyl)homopiperazine
- 1h-1,4-diazepine, hexahydro-1-(5-isoquinolinylsulfonyl)-
- at877
- at 877
- at-877
- at-877
- at-877
- eril
- fasudil
- fasudil
- fasudil
- fasudil
- fasudil
- fasudil
- fasudil
- fasudil hcl
- fasudil hcl semihydrate
- fasudil hcl semihydrate
- fasudil hcl semihydrate
- fasudil hcl semihydrate
- fasudil hydrochloride
- fasudil hydrochloride
- fasudil hydrochloride
- fasudil hydrochloride
- fasudil hydrochloride hydrate
- fasudil mesylate
- ha1077
- ha 1077
- ha-1077
- ha-1077
- ha-1077
- ha-1077
- zk-258594
- zk-258594
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07297693 | Phase 1 | Dec 19, 2025 | Hanmi Pharmaceutical |
| NCT06890858 | Phase 2 | Apr 30, 2025 | Zhejiang University |
| NCT06861192 | Phase 2/Phase 3 (Phase 3) | Feb 16, 2025 | Southeast University |
| NCT06362707 | Phase 2 | Aug 1, 2024 | Haraldsplass Deaconess Hospital, Helse Fonna, Norwegian University of Science and Technology, Oslo Metropolitan University, University of Exeter, University of Stavanger |
| NCT07250542 | Phase 2 | Jul 5, 2024 | Southeast University |
| NCT05931575 | Phase 2 | Sep 11, 2023 | Technical University of Munich |
| NCT05218668 | Phase 2 | Dec 22, 2021 | Woolsey Pharmaceuticals |
| NCT04734379 | Phase 2 | Jan 22, 2021 | University of California, San Francisco, Woolsey Pharmaceuticals |
| NCT04793659 | Phase 2 | Dec 15, 2020 | Woolsey Pharmaceuticals |
| NCT03753269 | Phase 4 | Jul 1, 2019 | Jiao Tong University |
| NCT04191954 | Phase 2/Phase 3 (Phase 3) | Jun 2, 2019 | Shahid Beheshti University of Medical Sciences |
| NCT03792490 | Phase 2 | Feb 20, 2019 | University of Goettingen |
| NCT03391219 | Phase 2/Phase 3 (Phase 3) | Jan 31, 2018 | Shahid Beheshti University of Medical Sciences |
| NCT03404843 | Phase 2 | Jul 14, 2017 | Colorado State University |
| NCT01935518 | Phase 2 | Sep 1, 2013 | Peking University |
| NCT01823081 | Phase 3 | Jan 1, 2013 | Shahid Beheshti University of Medical Sciences |
| NCT00670202 | Phase 2 | Mar 13, 2008 | Doris Duke Charitable Foundation, Harvard University |
| NCT00498615 | Phase 3 | Apr 1, 2007 | Johns Hopkins University |
| NCT00120718 | Phase 2 | Jun 1, 2002 | Harvard University |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (20)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shahid Beheshti University of Medical Sciences | Academic/Hospital | 3 | 3 | 1 | 2013 |
| Woolsey Pharmaceuticals | For profit | 3 | 3 | 1 | 2020 |
| Harvard University | Academic/Hospital | 2 | 2 | 1 | 2002 |
| Southeast University | Academic/Hospital | 2 | 2 | 2 | 2024 |
| Colorado State University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Doris Duke Charitable Foundation | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Hanmi Pharmaceutical | For profit | 1 | 1 | 1 | 2025 |
| Haraldsplass Deaconess Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Helse Fonna | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Norwegian University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Oslo Metropolitan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Technical University of Munich | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Exeter | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Goettingen | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Stavanger | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2025 |
20 organizations
Page 1 / 1